{
  "id": 13731026,
  "title": "Pacira BioSciences SVP Lauren Riker sells $217,920 in stock",
  "url": "https://urgent.news/2026/10/11/pacira-biosciences-svp-lauren-riker-sells-217-920-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T13:31:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pacira-biosciences-svp-lauren-riker-sells-217920-in-stock-93CH-4942682"
  },
  "original_language": "en",
  "account": "On October 8, 2026, Senior Vice President of Finance Lauren Riker at Pacira BioSciences sold 6,000 shares of the company's common stock for a total value of $217,920. The shares were sold at $36.32 per share, slightly below the stock's 52-week high of $36.46. This investment move came as the stock surged 44% in just a week, yet the company remains undervalued according to Fair Value analysis. Just before selling, Riker had bought 6,000 shares through stock options at $32.35 per share, investing $194,100. The transactions followed a Rule 10b5-1 trading plan adopted on March 12, 2026. Ms. Riker now directly owns 62,284.242 shares of Pacira BioSciences common stock. Meanwhile, Pacira reported a 6% increase in its second-quarter revenue to $192.4 million, beating expectations of $191.06 million. This growth was driven by the expansion of main products and a major payer coverage win. Viatris acquired Pacira Pharmaceuticals for $1.65 billion, prompting Jefferies to downgrade Pacira's stock rating to 'Hold' with a price target of $36.00. Despite this, Oppenheimer gave Pacira an 'Outperform' rating with a price target of $32.00, citing the strong commercial phase of Exparel, Pacira's product.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Pacific Biosciences CFO reports $2.05m stock sale",
        "url": "https://urgent.news/2026/10/10/pacific-biosciences-cfo-reports-2-05m-stock-sale",
        "published": "2026-10-10T17:31:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}